Publication: A roadmap for the development of ivermectin as a complementary malaria vector control tool
Issued Date
2020-01-01
Resource Type
ISSN
00029637
Other identifier(s)
2-s2.0-85079102482
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Tropical Medicine and Hygiene. Vol.102, (2020), 3-24
Suggested Citation
Peter Billingsley, Fred Binka, Carlos Chaccour, Brian D. Foy, Silvia Gold, Matiana Gonzalez-Silva, Julie Jacobson, George Jagoe, Caroline Jones, Patrick Kachur, Kevin Kobylinski, Anna Last, James V. Lavery, David Mabey, Leonard Mboera, Charles Mbogo, Ana Mendez-Lopez, N. Regina Rabinovich, Sarah Rees, Frank Richards, Cassidy Rist, Jessica Rockwood, Paula Ruiz-Castillo, Jetsumon Sattabongkot, Francisco Saute, Hannah Slater, Andrew Steer, Kang Xia, Rose Zulliger A roadmap for the development of ivermectin as a complementary malaria vector control tool. American Journal of Tropical Medicine and Hygiene. Vol.102, (2020), 3-24. doi:10.4269/ajtmh.19-0620 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/54587
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A roadmap for the development of ivermectin as a complementary malaria vector control tool
Author(s)
Peter Billingsley
Fred Binka
Carlos Chaccour
Brian D. Foy
Silvia Gold
Matiana Gonzalez-Silva
Julie Jacobson
George Jagoe
Caroline Jones
Patrick Kachur
Kevin Kobylinski
Anna Last
James V. Lavery
David Mabey
Leonard Mboera
Charles Mbogo
Ana Mendez-Lopez
N. Regina Rabinovich
Sarah Rees
Frank Richards
Cassidy Rist
Jessica Rockwood
Paula Ruiz-Castillo
Jetsumon Sattabongkot
Francisco Saute
Hannah Slater
Andrew Steer
Kang Xia
Rose Zulliger
Fred Binka
Carlos Chaccour
Brian D. Foy
Silvia Gold
Matiana Gonzalez-Silva
Julie Jacobson
George Jagoe
Caroline Jones
Patrick Kachur
Kevin Kobylinski
Anna Last
James V. Lavery
David Mabey
Leonard Mboera
Charles Mbogo
Ana Mendez-Lopez
N. Regina Rabinovich
Sarah Rees
Frank Richards
Cassidy Rist
Jessica Rockwood
Paula Ruiz-Castillo
Jetsumon Sattabongkot
Francisco Saute
Hannah Slater
Andrew Steer
Kang Xia
Rose Zulliger
Other Contributor(s)
University of Health and Allied Sciences, Ghana
Sanaria Inc.
Instituto de Salud Global de Barcelona
Ifakara Health Institute
Wellcome Trust Research Laboratories Nairobi
Universidad de Navarra
Harvard T.H. Chan School of Public Health
London School of Hygiene & Tropical Medicine
Columbia University in the City of New York
Virginia Polytechnic Institute and State University
University of Melbourne
Centers for Disease Control and Prevention
Armed Forces Research Institute of Medical Sciences, Thailand
Virginia-Maryland College of Veterinary Medicine
Mahidol University
Colorado State University
Emory University
International Public Health Advisors
Bridges to Development
Medicines for Malaria Venture
SACIDS Foundation for One Health
Fundación Mundo Sano
Innovative Vector Control Consortium
The Carter Center
PATH
Centro de Investigação em Saúde da Manhiça (CISM)
Sanaria Inc.
Instituto de Salud Global de Barcelona
Ifakara Health Institute
Wellcome Trust Research Laboratories Nairobi
Universidad de Navarra
Harvard T.H. Chan School of Public Health
London School of Hygiene & Tropical Medicine
Columbia University in the City of New York
Virginia Polytechnic Institute and State University
University of Melbourne
Centers for Disease Control and Prevention
Armed Forces Research Institute of Medical Sciences, Thailand
Virginia-Maryland College of Veterinary Medicine
Mahidol University
Colorado State University
Emory University
International Public Health Advisors
Bridges to Development
Medicines for Malaria Venture
SACIDS Foundation for One Health
Fundación Mundo Sano
Innovative Vector Control Consortium
The Carter Center
PATH
Centro de Investigação em Saúde da Manhiça (CISM)
Abstract
Copyright © 2020 by The American Society of Tropical Medicine and Hygiene. In the context of stalling progress against malaria, resistance of mosquitoes to insecticides, and residual transmission, mass drug administration (MDA) of ivermectin, an endectocide used for neglected tropical diseases (NTDs), has emerged as a promising complementary vector control method. Ivermectin reduces the life span of Anopheles mosquitoes that feed on treated humans and/or livestock, potentially decreasing malaria parasite transmission when administered at the community level. Following the publication by WHO of the preferred product characteristics for endectocides as vector control tools, this roadmap provides a comprehensive view of processes needed to make ivermectin available as a vector control tool by 2024 with a completely novel mechanism of action. The roadmap covers various aspects, which include 1) the definition of optimal dosage/regimens for ivermectin MDA in both humans and livestock, 2) the risk of resistance to the drug and environmental impact, 3) ethical issues, 4) political and community engagement, 5) translation of evidence into policy, and 6) operational aspects of large-scale deployment of the drug, all in the context of a drug given as a prevention tool acting at the community level. The roadmap reflects the insights of a multidisciplinary group of global health experts who worked together to elucidate the path to inclusion of ivermectin in the toolbox against malaria, to address residual transmission, counteract insecticide resistance, and contribute to the end of this deadly disease.